275 related articles for article (PubMed ID: 29472926)
21. Evaluation of Borrelia burgdorferi BbHtrA Protease as a Vaccine Candidate for Lyme Borreliosis in Mice.
Ullmann AJ; Russell TM; Dolan MC; Williams M; Hojgaard A; Weiner ZP; Johnson BJ
PLoS One; 2015; 10(6):e0128868. PubMed ID: 26076465
[TBL] [Abstract][Full Text] [Related]
22. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.
Comstedt P; Schüler W; Meinke A; Lundberg U
PLoS One; 2017; 12(9):e0184357. PubMed ID: 28863166
[TBL] [Abstract][Full Text] [Related]
23. New Insights Into CRASP-Mediated Complement Evasion in the Lyme Disease Enzootic Cycle.
Lin YP; Frye AM; Nowak TA; Kraiczy P
Front Cell Infect Microbiol; 2020; 10():1. PubMed ID: 32083019
[TBL] [Abstract][Full Text] [Related]
24. Immune evasion of Borrelia burgdorferi: insufficient killing of the pathogens by complement and antibody.
Kraiczy P; Skerka C; Kirschfink M; Zipfel PF; Brade V
Int J Med Microbiol; 2002 Jun; 291 Suppl 33():141-6. PubMed ID: 12141738
[TBL] [Abstract][Full Text] [Related]
25. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
[TBL] [Abstract][Full Text] [Related]
26. Structural basis for complement evasion by Lyme disease pathogen Borrelia burgdorferi.
Bhattacharjee A; Oeemig JS; Kolodziejczyk R; Meri T; Kajander T; Lehtinen MJ; Iwaï H; Jokiranta TS; Goldman A
J Biol Chem; 2013 Jun; 288(26):18685-95. PubMed ID: 23658013
[TBL] [Abstract][Full Text] [Related]
27. Design and development of a novel vaccine for protection against Lyme borreliosis.
Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U
PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015
[TBL] [Abstract][Full Text] [Related]
28. Structural Elucidation of a Protective B Cell Epitope on Outer Surface Protein C (OspC) of the Lyme Disease Spirochete, Borreliella burgdorferi.
Rudolph MJ; Davis SA; Haque HME; Weis DD; Vance DJ; Piazza CL; Ejemel M; Cavacini L; Wang Y; Mbow ML; Gilmore RD; Mantis NJ
mBio; 2023 Apr; 14(2):e0298122. PubMed ID: 36976016
[TBL] [Abstract][Full Text] [Related]
29. Pre-exposure Prophylaxis With OspA-Specific Human Monoclonal Antibodies Protects Mice Against Tick Transmission of Lyme Disease Spirochetes.
Wang Y; Kern A; Boatright NK; Schiller ZA; Sadowski A; Ejemel M; Souders CA; Reimann KA; Hu L; Thomas WD; Klempner MS
J Infect Dis; 2016 Jul; 214(2):205-11. PubMed ID: 27338767
[TBL] [Abstract][Full Text] [Related]
30. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
Eschner AK; Mugnai K
Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
[TBL] [Abstract][Full Text] [Related]
31. Coordinated expression of Borrelia burgdorferi complement regulator-acquiring surface proteins during the Lyme disease spirochete's mammal-tick infection cycle.
Bykowski T; Woodman ME; Cooley AE; Brissette CA; Brade V; Wallich R; Kraiczy P; Stevenson B
Infect Immun; 2007 Sep; 75(9):4227-36. PubMed ID: 17562769
[TBL] [Abstract][Full Text] [Related]
32. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences.
Earnhart CG; Marconi RT
Hum Vaccin; 2007; 3(6):281-9. PubMed ID: 17921702
[TBL] [Abstract][Full Text] [Related]
33.
Cramer NA; Socarras KM; Earl J; Ehrlich GD; Marconi RT
Infect Immun; 2024 Mar; 92(3):e0052923. PubMed ID: 38289123
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of RevA, a fibronectin-binding protein of Borrelia burgdorferi, as a potential vaccine candidate for lyme disease.
Floden AM; Gonzalez T; Gaultney RA; Brissette CA
Clin Vaccine Immunol; 2013 Jun; 20(6):892-9. PubMed ID: 23595502
[TBL] [Abstract][Full Text] [Related]
35. Enhanced protective efficacy of Borrelia burgdorferi BB0172 derived-peptide based vaccine to control Lyme disease.
Hassan WS; Giaretta PR; Rech R; Ollivault-Shiflett M; Esteve-Gasent MD
Vaccine; 2019 Sep; 37(37):5596-5606. PubMed ID: 31387750
[TBL] [Abstract][Full Text] [Related]
36. Development and optimization of OspC chimeritope vaccinogens for Lyme disease.
Izac JR; O'Bier NS; Oliver LD; Camire AC; Earnhart CG; LeBlanc Rhodes DV; Young BF; Parnham SR; Davies C; Marconi RT
Vaccine; 2020 Feb; 38(8):1915-1924. PubMed ID: 31959423
[TBL] [Abstract][Full Text] [Related]
37. Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.
Edmondson DG; Prabhakaran S; Norris SJ; Ullmann AJ; Piesman J; Dolan M; Probst C; Radzimski C; Stöcker W; Komorowski L
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27733423
[TBL] [Abstract][Full Text] [Related]
38. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines.
Nassal M; Skamel C; Vogel M; Kratz PA; Stehle T; Wallich R; Simon MM
Int J Med Microbiol; 2008 Jan; 298(1-2):135-42. PubMed ID: 17888729
[TBL] [Abstract][Full Text] [Related]
39. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test.
Callister SM; Schell RF; Case KL; Lovrich SD; Day SP
J Infect Dis; 1993 Jan; 167(1):158-64. PubMed ID: 8418162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
